ProMIS Neurosciences Inc.

Expert Comments:

Steve Silver, Argus Research (10/28/22) "ProMIS Neurosciences Inc.'s management expects to file a new drug application for PMN310 with the U.S. Food and Drug Administration by 2022E and to begin a Phase 1b clinical study in Alzheimer's disease patients in early 2023. . .importantly, the Phase 1b study will be an open-label, ascending-dose design and should provide monthly biomarker evidence that confirms both target engagement and product safety."
Clive Maund, CliveMaund.com (10/10/22) "ProMIS Neurosciences Inc. has a positive fundamental story, and the charts for its stock look most encouraging. . .with the price still close to the lows of this base pattern, this is a good time to buy the stock. . .it is therefore liked here and rated an Immediate Buy."
	Douglas Loe, Leede Jones Gable (9/30/22) "ProMIS Neurosciences Inc.'s Japan-based drug development peer, Eisai, reported positive Phase 3 Alzheimer's disease (AD) data that demonstrated statistically significant slowing of cognitive decline, which was apparent at time points as early as six months. . .it is clear that amyloid has been resurrected as a druggable target in AD pharmacology, and we believe that the protofibril selectivity of lecanemab's pharmacology was key to seeing a clear cognition signal in Clarity AD that prior amyloid-targeted monoclonal antibodies (for which degenerate binding to amyloid monomers and/or plaques) could not reveal."
Douglas Loe, Leede Jones Gable (9/28/22) "We remain positive about the role that ProMIS Neurosciences Inc.'s PMN-310 could play in mitigating Alzheimer's disease progression through its documented amyloid-oligomer-specific binding, and we are thus encouraged that a related monoclonal antibody that also targets an amyloid oligomer form has not solidly demonstrated clinical efficacy on mitigating cognitive impairment in a large and well-controlled Phase 3 study. We believe that Clarity AD/lecanemeb data thus provide supporting evidence for our PMN-310-based investment thesis for ProMIS and for the role of oligomers/protofibrils in AD pathophysiology."
Testing Confirms Drug Candidate Differs From Peers (8/10/22) read more >
Douglas Loe, Leede Jones Gable (8/5/22) "ProMIS Neurosciences Inc. and its scientific collaborators presented new preclinical/biochemical data that further characterized the beta amyloid-binding activity of the firm's novel monoclonal antibody (mAb) drug PMN310, showing in a series of experiments that the mAb has a unique binding profile when compared to other amyloid-targeted mAbs. . .new PMN310 amyloid binding data is consistent with our prior analysis showing how selectively PMN310 binds to neurotoxic beta amyloid oligomers and not to monomers or higher order plaques."
Steve Silver, Argus Research (7/6/22) "ProMIS Neurosciences Inc. has designated PMN267, focused on TDP-43, as its lead product candidate for treatment of amyotrophic lateral sclerosis (ALS). To date, an intrabody version of PMN267, delivered inside cells via a gene therapy vector, has shown significant reductions in the amount of TDP-43 aggregates in human motor neurons derived from ALS patients, and an injectable antibody treatment has produced promising trends for protection against disability."
Trial of New Alzheimer's Drug Slated for Early 2023 (7/1/22) read more >

More Expert Comments

	Douglas Loe, Leede Jones Gable (7/6/22) "Earlier this week, ProMIS Neurosciences Inc. competitor, Eisai, received priority review status from the U.S. Food and Drug Administration (FDA) for a Phase 3-stage beta amyloid-targeted monoclonal antibody called lecanemab. . .protofibril-targeted lecanemab exhibits binding selectivity to intermediate oligomeric forms of beta amyloid, and so favorable FDA review could reflect positively on PMN310's downstream clinical/regulatory prospects."
Steve Silver, Argus Research (6/27/22) "ProMIS Neurosciences Inc.'s PMN310 program is currently undergoing investigational new drug enabling activities and is expected to begin a Phase 1b clinical study in Alzheimer's disease patients in early 2023. . .we view PMN310 as potentially representing a best-in-class opportunity."
	Douglas Loe, Leede Jones Gable (5/11/22) "We are initiating coverage on Massachusetts-based, central nervous system-focused, antibody-based drug developer ProMIS Neurosciences Inc. with a Speculative Buy rating. . .the company's core competency lies in its expertise in generating monoclonal antibodies that target conformational epitopes that are expressed either predominantly or exclusively on misfolded or aggregated proteins that in being misfolded/aggregated contribute to disease."
Steve Silver, Argus Research (4/13/22) "We view ProMIS Neurosciences Inc.'s path to clinical value inflection favorably, given that its Phase 1b study will be open label and biomarker checked on a monthly basis, which should provide evidence of effect at a relatively early stage. In addition, we expect the appetite for mergers and acquisitions and financing for diseases such as Alzheimer's to improve over 2022, as new late-stage data is reported."

Experts Following This Company

	Douglas Loe, Managing Director & Analyst, Healthcare and Biotechnology – Leede Jones Gable
Clive Maund – CliveMaund.com
Steve Silver, Outside IR – KCSA Strategic Communications
John Vandermosten, CFA – Zacks Small-Cap Research

The information provided above is from analysts, newsletters, the company and other contributors.

ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.